(Total Views: 524)
Posted On: 07/16/2019 2:36:47 PM
Post# of 30015
![Avatar](https://investorshangout.com/images/ProfileImages/no_avatar_available.jpg)
“If confirmed at study completion, these results suggest that LymPro will be a useful adjunctive biological diagnostic test that adds confidence to a clinical AD diagnosis." -Todos incoming CMO Dr. Paula Trzepacz https://t.co/Wp9X0r8HUR $TOMDF #Alzheimers
https://twitter.com/todosmedical/status/11511...96352?s=19
Todos expects patient enrollment to complete in an ongoing study of LymPro in the second half of 2019 and to disclose full results in a future scientific conference https://t.co/Wp9X0r8HUR $TOMDF
https://twitter.com/todosmedical/status/11511...27488?s=19
For those who want to keep up.
Also, in every PR release as of late speaking of upcoming events, things have been completed not too far after the PR.
I wonder which future scientific conference they have their sights on.
Wonder how many more weeks till Todos' uplist?
Aloha
https://twitter.com/todosmedical/status/11511...96352?s=19
Todos expects patient enrollment to complete in an ongoing study of LymPro in the second half of 2019 and to disclose full results in a future scientific conference https://t.co/Wp9X0r8HUR $TOMDF
https://twitter.com/todosmedical/status/11511...27488?s=19
For those who want to keep up.
Also, in every PR release as of late speaking of upcoming events, things have been completed not too far after the PR.
I wonder which future scientific conference they have their sights on.
Wonder how many more weeks till Todos' uplist?
Aloha
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)